gemcitabine/Eloxatin (GEMOX) + carboplatin/paclitaxel (CP)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Mar 1, 2004 → —
NCT ID
NCT00087802About gemcitabine/Eloxatin (GEMOX) + carboplatin/paclitaxel (CP)
gemcitabine/Eloxatin (GEMOX) + carboplatin/paclitaxel (CP) is a phase 3 stage product being developed by Sanofi for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00087802. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00087802 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung